• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday

    6/13/24 10:17:19 AM ET
    $ACLS
    $AMSC
    $ANET
    $AVGO
    Industrial Machinery/Components
    Technology
    Metal Fabrications
    Consumer Discretionary
    Get the next $ACLS alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday.

    Shares of Tesla Inc (NASDAQ:TSLA) rose sharply during Thursday's session after CEO Elon Musk said the company’s shareholder resolutions are passing with significant margins.

    Meanwhile, Tesla said on Tuesday that it deployed two of its humanoid bots called Optimus at its factory this year where they are performing tasks autonomously.

    Tesla shares gained 6.7% to $189.30 on Thursday.

    Here are some other big stocks recording gains in today’s session.

    • NWTN Inc. (NASDAQ:NWTN) shares rose 22.8% to $1.84.
    • John Wiley & Sons, Inc. (NYSE:WLYB) gained 19.3% to $42.62 as the company reported results for the fourth quarter and fiscal year ended April 30, 2024.
    • Kyverna Therapeutics, Inc. (NASDAQ:KYTX) climbed 17.3% to $16.10.
    • American Superconductor Corporation (NASDAQ:AMSC) rose 14.3% to $26.92. Roth MKM analyst Justin Clare maintained American Superconductor with a Buy and raised the price target from $20 to $27.
    • Broadcom Inc. (NASDAQ:AVGO) rose jumped 14.2% to $1,707.99 after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion.
    • Bitfarms Ltd. (NASDAQ:BITF) gained 12.3% to $2.73. The company on Thursday issued new guidance for 2025 after announcing an agreement to develop power capacity in Pennsylvania.
    • United Homes Group, Inc. (NASDAQ:UHG) rose 12.3% to $7.34.
    • Verona Pharma PLC – ADR (NASDAQ:VRNA) shares gained 12% to $16.52.
    • Bilibili Inc – ADR (NASDAQ:BILI) climbed 10.6% to $15.91.
    • Vanda Pharmaceuticals Inc (NASDAQ:VNDA) gained 10.1% to $6.52 after Future Pak increased the cash portion of its offer to $8.50-$9.00 per share.
    • Cipher Mining Inc (NASDAQ:CIFR) gained 8.4% to $4.96.
    • Core Scientific, Inc. (NASDAQ:CORZ) gained 8.3% to $10.36.
    • Korn Ferry (NYSE:KFY) climbed 7% to $67.87 following better-than-expected quarterly results.
    • Axcelis Technologies Inc (NASDAQ:ACLS) shares gained 5% to $143.40.
    • Insmed Inc (NASDAQ:INSM) rose 5% to $64.70.
    • Arista Networks Inc (NYSE:ANET) shares gained 5% to $326.78 after Morgan Stanley maintained an Overweight rating and raised its price target from $300 to $325.
    • NVIDIA Corp (NASDAQ:NVDA) gained 3.1% to $129.06 on continued momentum. The stock recently underwent a stock split.

    Now Read This: Wall Street’s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields

    Get the next $ACLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLS
    $AMSC
    $ANET
    $AVGO

    CompanyDatePrice TargetRatingAnalyst
    Broadcom Inc.
    $AVGO
    2/13/2026$335.00Neutral
    DA Davidson
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Cipher Mining Inc.
    $CIFR
    2/9/2026$38.00Overweight
    Morgan Stanley
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Broadcom Inc.
    $AVGO
    1/30/2026$400.00Peer Perform → Outperform
    Wolfe Research
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Bitfarms Ltd.
    $BITF
    1/27/2026$3.00Outperform → Mkt Perform
    Keefe Bruyette
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    More analyst ratings

    $ACLS
    $AMSC
    $ANET
    $AVGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson initiated coverage on Broadcom with a new price target

    DA Davidson initiated coverage of Broadcom with a rating of Neutral and set a new price target of $335.00

    2/13/26 8:31:21 AM ET
    $AVGO
    Semiconductors
    Technology

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Morgan Stanley initiated coverage on Cipher Mining with a new price target

    Morgan Stanley initiated coverage of Cipher Mining with a rating of Overweight and set a new price target of $38.00

    2/9/26 7:01:11 AM ET
    $CIFR
    Finance: Consumer Services
    Finance

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CTO Duda Kenneth exercised 32,000 shares at a strike of $15.26 and sold $8,259,002 worth of shares (58,000 units at $142.40) (SEC Form 4)

    4 - Arista Networks, Inc. (0001596532) (Issuer)

    2/19/26 8:43:26 PM ET
    $ANET
    Computer Communications Equipment
    Telecommunications

    SVP, Chief Marketing Officer Wijkstrom Joakim was granted 125,000 shares, increasing direct ownership by 52% to 364,269 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    2/19/26 5:53:58 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Business Development Birznieks Gunther was granted 125,000 shares, increasing direct ownership by 30% to 536,628 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    2/19/26 5:51:59 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLS
    $AMSC
    $ANET
    $AVGO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Core Scientific Inc.

    SCHEDULE 13D/A - Core Scientific, Inc./tx (0001839341) (Subject)

    2/19/26 9:17:28 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/19/26 4:31:34 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Core Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K/A - Core Scientific, Inc./tx (0001839341) (Filer)

    2/19/26 11:56:03 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

    WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity (NCE) that belongs in the class of atypical antipsychotics. In clinical studies BYSANTI™ demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum enabling it to leverage well

    2/20/26 5:59:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Broadcom Introduces Industry's First 6G Digital Front-End SoC for Massive MIMO

    PALO ALTO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ:AVGO), a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions, today announced the launch of BroadPeak™, a highly integrated radio digital front-end (DFE) SoC device, unlocking new possibilities for 5G massive multiple-input multiple-output (MIMO) and remote radio head (RRH) applications and paving the path for next-generation 5G Advanced and 6G wireless infrastructure. The device features state-of-the-art 5nm CMOS DFE and ADC/DAC blocks on a single chip, delivering up to 40% power reduction over existing solutions for massive MIMO and RRHs. With breakthrou

    2/19/26 9:00:00 AM ET
    $AVGO
    Semiconductors
    Technology

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director You Harry L. bought $325,129 worth of shares (1,000 units at $325.13), increasing direct ownership by 3% to 36,602 units (SEC Form 4)

    4 - Broadcom Inc. (0001730168) (Issuer)

    12/22/25 5:34:40 PM ET
    $AVGO
    Semiconductors
    Technology

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Leadership Updates

    Live Leadership Updates

    View All

    Cipher Welcomes Thomas Duda to the Company's Board of Directors

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ:CIFR) ("Cipher" or the "Company"), a leading developer and operator of industrial-scale data centers, today announces the appointment of Thomas Duda to its Board of Directors. Mr. Duda has more than twenty years of real estate-focused investment experience, further strengthening the Board as Cipher executes its pivot to becoming a world leader in data center development and operations. Mr. Duda currently serves as Vice President of Real Estate at Henry Crown and Company, where he leads the firm's real estate investment and asset management activities, and is a member of the Investment and Management Committee. Previous

    2/11/26 4:05:00 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitfarms Announces Board Chair Transition in Anticipation of U.S. Redomiciliation

    TORONTO, Ontario and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX:BITF) ("Bitfarms" or the "Company"), a North American energy and digital infrastructure company, today announced that Edie Hofmeister has been appointed as Chair of the Board of Bitfarms. This appointment supports Bitfarms' previously announced strategy of redomiciling to the United States. Ms. Hofmeister succeeds Brian Howlett who has served as Director since 2020, and Chairman since 2024. Mr. Howlett will continue to serve as an Independent Director. Ms. Hofmeister brings over two decades of extensive expertise in legal affairs, corporate governance, and business strategy, developed over years in

    1/14/26 7:00:00 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Financials

    Live finance-specific insights

    View All

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axcelis Announces Financial Results for Fourth Quarter and Full Year 2025

    Q4 Highlights:Revenue of $238 millionGAAP Gross Margin of 47.0%, and Non-GAAP Gross Margin of 47.3%GAAP Operating Margin of 15.2% and Non-GAAP Operating Margin of 21.1%GAAP Diluted Earnings Per Share of $1.10, and Non-GAAP Diluted Earnings Per Share of $1.49BEVERLY, Mass., Feb. 17, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the fourth quarter and full year ended December 31, 2025. President and CEO Russell Low commented, "Axcelis exited 2025 on a strong note with fourth quarter results that exceeded our outlook. We achieve

    2/17/26 4:01:00 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Arista Networks, Inc. Reports Fourth Quarter and Year End 2025 Financial Results

    Arista Networks, Inc. (NYSE:ANET), an industry leader in data-driven, client-to-cloud networking for large AI, data center, campus, and routing environments, today announced financial results for its fourth quarter and the full year ended December 31, 2025. "2025 was the year of validation of our Arista 2.0 momentum, as we hit the milestone of shipping a cumulative of 150 million ports," stated Jayshree Ullal, Chairperson and CEO of Arista Networks. "We exceeded both our AI networking and campus expansion goals, delivering profitable growth and revenue of $9 billion." Fourth Quarter Financial Highlights Revenue of $2.488 billion, an increase of 7.8% compared to the third quarter of 2

    2/12/26 4:05:00 PM ET
    $ANET
    Computer Communications Equipment
    Telecommunications

    $ACLS
    $AMSC
    $ANET
    $AVGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by United Homes Group Inc

    SC 13G - United Homes Group, Inc. (0001830188) (Subject)

    12/17/24 5:44:48 PM ET
    $UHG
    Homebuilding
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by United Homes Group Inc

    SC 13D/A - United Homes Group, Inc. (0001830188) (Subject)

    12/13/24 6:24:20 PM ET
    $UHG
    Homebuilding
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by United Homes Group Inc

    SC 13D/A - United Homes Group, Inc. (0001830188) (Subject)

    12/9/24 7:16:21 PM ET
    $UHG
    Homebuilding
    Consumer Discretionary